Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure  by McGonigle, Richard J.S. et al.
Kidney International, Vol. 25 (1984), pp. 430—436
Hemodialysis and continuous ambulatory peritoneal dialysis
effects on erythropoiesis in renal failure
RICHARD J. S. MCGONIGLE, FRED HUSSERL, JOHN D. WALLIN, and JAMES W. FISHER
Department of Pharmacology and Internal Medicine (Nephrology), Tulane University School of Medicine, and Department of Medicine,
Section on Renal Disease, Ochsner Medical Institutions, New Orleans, Louisiana
Hemodialysis and continuous ambulatory peritoneal dialysis effects on
erythropoiesis in renal failure. Parameters of erythropoiesis were stud-
ied in patients with endstage renal disease established on continuous
ambulatory peritoneal dialysis (CAPD) and regular hemodialysis treat-
ment (RDT). Serum erythropoietin was measured by radioimmunoas-
say, and erythroid progenitor cell (CFU-E) formation was assayed in
fetal mouse liver cultures. Serum erythropoietin concentrations in both
CAPD (35.3 4.0 mU/mi) and RDT (31.9 1.9 mU/mi) patients were
significantly higher (P < 0.01) than normal values (23.1 1.0 mU/mi).
The serum erythropoietin concentration did not correlate with either
hematocrit or inhibition of CFU-E formation in either group of dialysis
patients. In both CAPD and RDT patients the hematocrit correlated
significantly (P < 0.001) with the degree of serum inhibition of CFU-E
formation. CFU-E formation decreased from 74.5 2.5 to 62.5 3.5%
of control with increasing concentrations of uremic serum in cell
cultures from 5 to 20%. In RDT patients a single hemodialysis produced
a decrease in the mean serum erythropoietin concentration from 31.8
2.1 to 27.4 1.8 mU/ml (P < 0.01) but no significant change in CFU-E
formation. In conclusion, although serum immunoreactive erythropoie-
tin levels are elevated above the normal range in dialysis patients, the
response remains inadequate for the severity of the anemia, and it is the
degree of serum inhibition of erythropoiesis in both CAPD and RDT
patients which correlates with and possibly determines the degree of
anemia.
Effets de l'hémodialyse et de Ia dialyse péritonéale continue ambulatoire
sur l'erythropoiese au cours de l'insuflIsance rénale. Les paramètres de
l'erythropoIese ont Cté Ctudiés chez des malades avec une n6phropathie
terminale en dialyse péritonéale continue ambulatoire (CAPD) et en
hemodialyse périodique (RDT). L'Crythropoiétine serique a été me
surée par dosage radioimmunologique, et Ia formation de ceiluies
souches erythroides (CFU-E) a été dosée dans des cultures de foie
foetal de souris. Les concentrations d'erythropoiétine sérique chez les
malades en CAPD (35,3 4,0 mU/mi) et en RDT (31,9 1,9 mU/mi)
Ctaient significativement plus élevdes (P < 0,01) que les valeurs
normales (23,1 1,0 mU/mi). La concentration d'erythropoiCtine
serique n'Ctait corrélée ni a l'hCmatocrite, ni a l'inhibition deformation
de CFU-E dans aucun groupe d'hémodialysés. Chez les malades en
CAPD et en RDT, l'hématocrite était significativement corrélé (P <
0,001) avec le degré d'inhibition sérique de formation de CFU-E. La
formation de CFU-E diminuait de 74,5 2,5 a 62,5 3,5% du contrôle
en augmentant les concentrations de serum uremique dans les cultures
cellulaires de 5 a 20%. Chez les malades en RDT, une hémodialyse
unique entrainait une diminution de la concentration d'erythropoietine
sCrique moyenne de 31,8 2,1 a 27,4 1,8 mU/mi (P <0,01), mais pas
de changement significatif dans la formation de CFU-E. En conclusion,
bien que les niveaux d'erythropoICtine immunoréactive serique soient
éievés au-dessus de Ia normale chez les malades en dialyse, la reponse
reste inadequate compte tenu de Ia sCvérité de l'anémie, et c'est le
degre d'inhibition serique de l'erythropoièse chez des malades en
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CAPD et en RDT qui est corrélCe avec et peut-Ctre determine le degré
d'anémie.
Continuous ambulatory peritoneal dialysis (CAPD) has been
reported to produce an improvement in the anemia associated
with endstage renal disease as indicated by the hematocrit 1—
5]. An increase in hemoglobin levels over a period of months to
years with regular hemodialysis therapy (RDT) has also been
reported [6—81. Fisher [9] reviewed the major factors involved
in the mechanism of the anemia of chronic renal failure includ-
ing erythropoietin deficiency, inhibition of erythropoiesis, and
shortened red cell life span. In vitro membrane dialysis has
been shown to partially remove inhibitors of erythroid progeni-
tor cell formation including inhibitors of both CFU-E (colony
forming unit-erythroid) and BFU-E (burst forming unit-ery-
throid) formation [10—12]. The improvement in anemia in pa-
tients on CAPD may be related to a more efficient removal of
"middle-molecule" uremic toxins [1, 2, 13] which have been
considered responsible for the inhibition of erythropoiesis [10,
14}. Alternative explanations include an improvement in red
cell survival time in patients on CAPD, since hemolysis persists
and may even be exacerbated by hemodialysis in addition to the
effects of uremia [15, 161. The increased blood loss from the
dialyzer unit, together with blood loss from various other
sources [17, 181 would also tend to aggravate the anemia found
in patients on RDT. A recent report showed that the increase in
hematocnt of patients starting CAPD reflects a decrease in
plasma volume in addition to an increase in red cell mass [191.
Heretofore, serum levels of erythropoietin and inhibitors of
erythropoiesis have not been compared in patients on CAPD
and RDT. This study was designed to examine the reported
erythropoietin deficiency associated with the anemia of renal
failure in patients on CAPD and in patients receiving RDT and
to assess the effect of the two forms of dialysis on erythropoie-
sis in the fetal mouse liver cell culture system.
Methods
Patients
Two groups of patients were studied after informed consent
had been obtained: (I) Forty-six patients established on regular
hemodialysis treatment (RDT) were investigated. Their ages
ranged from 15 to 79 years (mean SEM, 52.5 2.1 years) and
they had been receiving hemodialysis for periods ranging from 2
to 94 months (mean SEM, 35.7 4.1 months). The majority of
patients were on dialysis 4 hr three times per week using a
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standard 1 m2 dialyzer. The etiology of endstage renal disease in
these patients included hypertension, 14 patients; diabetes
mellitus, 9; glomerulonephritis, 4; chronic pyelonephritis, 3;
polycystic kidney disease, 12; Alport syndrome, 1; nephrocal-
cinosis, 2; obstructive uropathy, 1; and lupus nephritis, 1. Most
patients were receiving oral vitamin supplementation, but no
patient was receiving androgen therapy.
(2) Thirty-six patients established on CAPD were studied.
Their ages ranged from 20 to 77 years (mean SEM, 50.6 2.6
years) and had been on CAPD 1 to 38 months (mean SEM,
15.7 2.6 months). Standard 2-liter exchanges were performed
four times each day. The etiology of renal disease included
polycystic kidney disease, 4 patients; diabetes mellitus, 6;
glomerulonephritis, 9; obstructive uropathy, 3; chronic intersti-
tial nephritis, 1; congenital renal dysplasia, 1; hypertension, 6;
lupus nephritis, 1; and unknown, 5. Two patients were surgical-
ly anephric. All patients were receiving oral vitamin supplemen-
tation, but no patient was adminstered iron or androgen
treatment.
Blood was drawn immediately before and after hemodialysis
or at the time of exchange of peritoneal dialysis bags. The blood
was centrifuged and the serum was frozen at —70°C. No patient
was studied within 2 weeks of a blood transfusion. Patients on
CAPD and RDT had minimal residual renal function with
creatinine clearances all less than 5 ml/min. The iron status in 26
patients on RDT and 18 patients on CAPD was assessed by
measurement of the serum ferritin concentration.
Investigations
Radioimmunoassay for serum erythropoietin [20]. Highly
purified erythropoietin (70,400 U/mg protein) obtained from the
National Heart, Lung and Blood Institute, Bethesda, Maryland,
and prepared by Dr. Eugene Goldwasser's laboratory at the
University of Chicago was labelled with iodine- 125 by the
chloramine T method. A human erythropoietin antiserum was
prepared in rabbits. A human urinary erythropoietin prepara-
tion with a specific activity of 80 U/mg protein obtained from
the National Heart, Lung and Blood Institute was used for the
immunization. The antiserum was absorbed with normal human
serum and urinary proteins to increase the specificity for the
assay for erythropoietin. A second antibody (goat antirabbit
gamma globulin) was used for the separation of bound from
free-labeled antigen.
Fetal mouse liver cell culture technique. Mouse (CD-l) liver
cells from fetuses 12 to 13 days old, known to be predominantly
erythroid committed, were prepared according to the technique
of Iscove, Sieber, and Winterhalter [21]. Liver cells were
disaggregated and suspended as single cells at a concentration
of io cells/mi in a culture medium containing alpha modified
Eagle's medium with Earle's salts, and without ribosides,
deoxyribosides, and glutamine in methylcellulose, 30% fetal
calf serum, 100 mU of human urinary erythropoietin', 0.1 LM
mercaptoethanol, 100 mU of penicillin, and 100 sg of strepto-
1 Human urinary erythropoietin was supplied by the Department of
Physiology, University of Northeast, Corrientes, Argentina. The mate-
rial was further processed and assayed by the Hematology Research
Laboratories, Children's Hospital of Los Angeles, under United States
Public Health Service research grant HE-10880 (National Heart, Lung
and Blood Institute).
Fig. 1. Hematocrit levels in patients on continuous ambulatory perito-
neal dialysis CAPD and on regular hemodialysis treatment (RDT).
Numbers are means SEM. The asterisk represents values significantly
higher (P < 0.05) than RDT patients.
mycin. Human serum samples were heat-inactivated at 56°C for
30 mm and sterile-filtered before being tested at concentrations
of 5, 10, and 20%; the amount of fetal calf serum was altered
accordingly to maintain a total serum concentration of 30%.
Cell cultures (1 ml) were plated in 10 x 35 mm petri dishes
and incubated for 48 hr at 37°C in a humidified atmosphere at
95% air and 5% CO2. After staining of the plates with diamino-
benzidine according to the method of Ogawa et al [22], CFU-E
of eight or more cells were counted in four replicate plates using
an inverted microscope. One sixteenth of the plate area was
counted and considered representative of the total plate area
since very large numbers of colonies were present (1000 to 5000
colonies/plate). Only one batch of fetal calf serum (Flow
Laboratories 29101607) and one batch of erythropoietin1 (sp act
10 U/mg protein) were used to minimize variations in erythroid
colony formation. Human serum from one subject was used as a
standard control. CFU-E formation was expressed as a percent-
age of the control.
Statistical analysis. The Student's t test, paired t test, and
linear regression analysis were used for statistical comparisons.
Results
The age and sex distribution of each group of dialysis patients
used in the present studies were similar. Patients had been
receiving RDT for a longer period of time than patients on
CAPD. No clinical evidence of blood loss or iron deficiency
was detected in either group of patients. The mean serum
ferritin concentration in RDT patients was 439 77 hg/liter
(range, 47 to 1293 /Lg/liter), and in CAPD patients 190 40
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Fig. 2. Serum erythropoietin concentrations in 40 normal subjects, 60
patients with varying degrees of renal insufficiency not on dialysis, 46
patients receiving regular hemodialysis treatment (RDT) and 30 pa-
tients on continuous ambulatory peritoneal dialysis (CAPD). Numbers
are means SEM. The asterisk represents values significantly higher (P
<0.01) than the normal range. The open circles represent patients with
polycystic kidney disease.
g!liter (range, 33 to 500 pg/liter). One patient on CAPD with a
diagnosis of myelofibrosis was excluded from the study. He-
matocrit levels were significantly (P < 0.05) higher in patients
established on CAPD (mean, 30.4 1.3%) in comparison to
patients receiving RDT (mean, 25.9 1.4%) though in both
groups a wide range in the severity of anemia was seen (Fig. 1).
RDT patients in whom the etiology of renal failure was due to
polycystic kidney disease had significantly higher (P < 0.05)
hematocrit values (mean, 31.6 1.9%) than RDT patients with
renal disease due to other causes (mean, 25.9 1.6%). Similar-
ly two of the three patients on CAPD with a diagnosis of
polycystic kidney disease had elevated hematocrit levels above
45%.
Serum erythropoietin levels were significantly elevated (P <
0.01) above the normal range of 13.5 to 48 mU/mi (mean, 23.0
1.0 mU/mi) in both CAPD (35.3 4.0 mU/mi) and RDT (31.9
1.9 mU/mi) patients (Fig. 2). No significant difference was seen
in the mean serum erythropoietin concentration between the
two groups of dialysis patients. Patients with poiycystic kidney
disease receiving RDT had similar serum erythropoietin levels
in comparison to patients also on regular hemodialysis with
other forms of renal disease (35.7 6.7 vs. 31.6 2.0 mU/mi).
Of 60 patients studied with varying degrees of renal insufficien-
cy who had not started dialysis treatment serum erythropoietin
levels were normal in 54 patients and elevated in 6 patients.
Three of these patients had markedly elevated serum erythro-
poietin concentrations for which no explanation was found.
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Fig. 4. Relationship between serum erythropoietin concentration and
hematocrit in patients on continuous ambulatory peritoneal dialysis
(CAPD).
A wide scatter of serum erythropoietin concentrations in
patients receiving RDT showed no relationship to the patients'
hematocrit levels (Fig. 3). Patients on CAPD also showed no
significant association between hematocrit and serum erythro-
poietin concentration. However, there was a trend (r = 0.31)
toward a correlation between the hematocrit and erythropoietin
levels in that a higher hematocrit level was related to more
elevated serum erythropoietin concentrations (Fig. 4). There
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Fig. 3. Relationship between hematocrit and serum erythropoietin
concentration in patients receiving regular hemodialysis treatment
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Fig. 6. Relationship between serum erythropoietin concentration and
inhibition of CFU-E formation by sera from patients on RDT.
was no significant relationship between the serum erythropoie-
tin concentrations and the percentage inhibition of erythroid
colony formation by serum in either CAPD patients (Fig. 5) or
patients receiving RDT (Fig. 6). Inhibition of erythroid progeni-
tor cell (CFU-E) colony formation was seen in all patients
receiving CAPD or RDT in whom the hematocrit was less than
Fig. 8. The direct relationship between inhibition of erythroid colony
formation and hematocrit in patients receiving RDT. The concentration
of patient's serum in cultures is 5%.
35%. The degree of inhibition of CFU-E formation correlated
directly with the hematocrit in both CAPD patients (r = 0.767,
P < 0.001, Fig. 7) and RDT patients (r = 0.65, P <0.001, Fig.
8). The more severe the anemia the greater the degree of
inhibition of erythroid colony formation by uremic serum in cell
culture. The relationship between the hematocrit value and the
effect of serum on CFU-E formation was similar in the two
groups of dialysis patients using the method of least squares for
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plotting the linear regression line. CFU-E formation was pro-
gressively reduced (P < 0.05) from 74.5 2.5% to 62.7 3.5%
of control when increasing concentrations (5 to 20%) of uremic
sera were added to the fetal mouse liver cell cultures (Fig. 9).
The difference between the effects of normal serum and uremic
serum on CFU-E formation was highly significant (P < 0.001) at
each of the different concentrations of serum in culture tested.
Serum erythropoietin concentrations measured immediately
before and after a single 4-hr hemodialysis showed a significant
(P < 0.01) decrease from a mean of 31,8 2.1 to 27.4 1.8
mU/ml (Fig. 10). The mean value for erythroid colony forma-
tion also showed a slight but not statistically significant de-
crease from 76.0 1.9 to 73.0 1.3% of control (Fig. 11).
Discussion
Regular hemodialysis therapy (RDT) and continuous ambula-
tory peritoneal dialysis (CAPD) have both been reported to lead
to an improvement in the anemia associated with endstage renal
disease [1—8]. However, a large proportion of RDT and CAPD
patients remains anemic. The often greater improvement in
hematocrit levels during the first 6 months of CAPD treatment
in comparison to RDT has been reported to be due to a
reduction in plasma volume in addition to an increase in red cell
mass [19]. CAPD is associated with a much greater clearance of
middle molecular weight substances and a less efficient removal
of small molecular weight substances in comparison to hemodi-
alysis [1]. These observations have led several investigators to
suggest that uremic toxins responsible for inhibition of erythro-
poiesis are middle molecular weight in size and that it is the
difference in relative clearances of these inhibitors of erythro-
poiesis by RDT and CAPD which is responsible for any
difference in effect of the two forms of dialysis on the anemia of
renal failure [2, 31.
In this study we have examined parameters of erythropoiesis
in both CAPD and RDT patients. Although significantly elevat-
Fig. 10. Decrease in serum erythropoietin concentration immediately
before and after a single 4-hr hemodialysis in patients receiving RDT.
Values are expressed as means SEM.
ed above the normal range in the two groups of dialysis
patients, the mean serum erythropoietin concentration was
inappropriately low for the degree of anemia confirming the
importance of a relative erythropoietin deficiency in the anemia
of renal failure. Several investigators have measured serum
erythropoietin levels in patients with renal disease using a
radioimmunoassay [23—25], but only small numbers of patients
have been studied. Cotes [23] reported eight anephric patients
with serum erythropoietin levels ranging from < 5 to 99 mU/mi.
Zaroulis, Hoffman, and Kourides [25] showed a range for serum
erythropoietin concentration of 18 to 115 mU/mi (mean SD
40.5 30 mU/ml) in 11 patients with renal failure on regular
hemodialysis. Utilizing the fetal mouse liver cell bioassay
DeKlerk et a! [26] found decreased serum erythropoietin levels
in nephric patients on hemodialysis, and a significant positive
correlation between hemoglobin and serum erythropoietin in
nephric dialysis patients who were transfusion independent.
Caro et al [271 reported serum erythropoietin levels in 25
patients undergoing chronic hemodialysis using the polycythe-
mic mouse bioassay and a plasma concentration technique.
Eight of 11 anephric patients had decreased but detectable
levels of erythropoietin. Erythropoietin production was report-
ed to be more variable in the nephric dialysis patients with both
normal and elevated erythropoietin levels. The authors suggest-
ed that the difference may have been due to different degrees of
marrow unresponsiveness related to hyperparathyroidism.
The fetal mouse liver CFU-E culture used in our experiments
served as a convenient system to detect inhibition of erythro-
poiesis by uremic serum and does not necessarily reflect all of
the in vivo effects of uremic serum on the erythroid progenitor
cells in the marrow. However, the response of fetal mouse liver
cell cultures to both erythropoietin and uremic serum does
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Fig. 11. The change in effect of serum from patients receiving RDT on
CFU-E formation immediately before and after a single 4-hr hemodial-
ysis. Values are expressed as means SEM. The concentration of serum
in cultures is 5%.
closely parallel the response of human bone marrow cultures
[12].
In the present studies it was the degree of inhibition of CFU-
E formation rather than the serum erythropoietin concentration
which correlated with the hematocrit. The continuing close
association between hematocrit and inhibition of CFU-E forma-
tion in patients with endstage renal disease receiving either
CAPD or RDT suggests that it is the degree of inhibition of
erythropoiesis which determines the severity of anemia. An
inverse relationship between hematocrit and both inhibition of
heme synthesis in rabbit erythroblasts and mouse marrow
CFU-E has been described previously in patients receiving
long-term hemodialysis [28]. Neither form of dialysis appeared
very efficient in clearing inhibitors of erythropoiesis from the
serum of uremic patients, and the degree of abnormal erythro-
poiesis appeared very similar in the two groups of dialysis
patients. The uremic toxins responsible for inhibition of eryth-
ropoiesis may be of small molecular weight size but not
removed by dialysis due to intracellular or serum protein
binding.
Zappacosta, Caro, and Erslev [5] reported that patients on
CAPD in whom anemia improved had higher serum erythropoi-
etin concentrations than those patients in whom the hematocrit
remained unchanged. This study was retrospective and only
involved a small number of patients. We did not confirm these
findings in that in our studies the serum erythropoietin concen-
tration was not associated with either the hematocrit nor related
to changes in hematocrit in patients receiving CAPD. Patients
with polycystic kidney disease receiving RDT had higher he-
matocrit levels than RDT patients with endstage renal disease
due to other causes. This was not due to higher serum erythro-
poletin concentrations in our patients with polycystic kidney
disease as was proposed by Zappacosta, Caro, and Erslev [5]
for the polycystic kidney patients in their studies. Erythrocyto-
sis has been reported in patients on long-term hemodialysis in
whom the etiology of renal failure was due to polycystic kidney
disease [29], diffuse parenchymal renal disease [30], and ac-
quired cystic disease of endstage kidneys [31]. Elevated eryth-
ropoietin levels and erythrocytosis have been reported in
dialysis patients with liver disease, in particular, hepatitis [32],
but no patient in our studies had clinical or biochemical
evidence for hepatocellular dysfunction.
In vitro dialysis has been reported to remove inhibitors of
erythropoiesis [10, 11]. It is of interest that we found a
reduction in CFU-E formation following a single 4-hr hemodial-
ysis. Although this decrease in CFU-E formation did not
achieve significance, it did parallel a significant fall in serum
erythropoietin concentration. A decline in serum erythropoietin
over a period of months of regular hemodialysis has been
reported by Radtke et al [8]. However, Radtke et a! used a fetal
mouse liver cell assay for erythropoietin which is an in vitro
biological assay subject to the variable effects of inhibitors of
CFU-E formation also present in uremic serum. In contrast, the
radioimmunoassay used in the present study was capable of
accurately detecting small changes in serum erythropoietin
concentrations. Nevertheless, the fall in serum erythropoietin
concentration following a single hemodialysis was surprising in
that the molecular weight of erythropoietin has been reported
variously between 23,000 to 39,000 daltons [33—35] and would
not therefore be expected to be cleared through a cuprophan
membrane. It appears possible that the radioimmunoassay
detects immunologically reactive fragments of erythropoietin
sufficiently small to be removed by hemodialysis. Immunoreac-
tive fragments of erythropoietin considerably smaller than the
whole hormone and without biological activity have been
postulated to be present in the sera of uremic patients [36].
Other factors affecting erythropoietin production or release
may account for the change in serum levels during hemodialy-
sis. A diurnal variation of serum immunoreactive erythropoietin
has been described in normal subjects [37]. Postural changes
may also possibly affect erythropoietin production since an
interrelationship between the renin system and erythropoietin
has been demonstrated [381. It is also possible that a lack of
reproducibility in the radioimmunoassay might account for
these changes.
In conclusion, this study has demonstrated the continuing
presence of inhibition of erythropoiesis in both patients receiv-
ing regular hemodialysis treatment and those on continuous
ambulatory peritoneal dialysis. In addition, a close relationship
between the severity of the anemia of renal failure and the
degree of inhibition of CFU-E formation in the two groups of
dialysis patients was seen. Serum erythropoietin levels were
moderately elevated above the normal range but still represent-
ed a relative deficiency and had no positive correlation with the
degree of anemia.
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